Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Articles published by Fresenius Kabi
< Previous
1
2
Next >
Fresenius Kabi Expands Women’s Health Portfolio with New Generic Option for Reproductive Health
August 27, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Receives 2024 Trailblazer Award From Premier Inc. for Supply Chain Innovation
August 05, 2024
From
Fresenius Kabi
Via
Business Wire
Arunesh Verma Joins Fresenius Kabi USA as President
July 10, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Continues its Biopharma Momentum with Launch of Subcutaneous Formulation of Tyenne® (tocilizumab-aazg) in the United States
July 02, 2024
From
Fresenius Kabi
Via
Business Wire
Angels for Change 2024 Drug Shortage Guardian Award Presented to Fresenius Kabi USA
June 06, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®, its Third Approved Biosimilar in the U.S.
April 15, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Further Expands Oncology Portfolio with Launch of Cyclophosphamide for Injection, USP
February 28, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Launches Posaconazole Injection for Prevention or Treatment of Fungal Infections
January 29, 2024
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi and Mayo Clinic Enter into Multiyear Supply and Service Agreement for the Ivenix® Infusion System
December 14, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Celebrates 25th Anniversary of National Blood Donation Hall of Fame by Honoring 2023 Heroes
October 10, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Introduces Smart Labels for Diprivan® with Embedded Fully Interoperable +RFID Technology
October 09, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Named 2023 Supplier Partner of the Year by Vizient
October 03, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Selected for Second Consecutive Year to Exhibit the Ivenix Infusion System at Vizient Innovative Technology Exchange
October 02, 2023
From
Fresenius Kabi
Via
Business Wire
Virginia Oncology Associates Chooses the Ivenix Infusion System from Fresenius Kabi
September 14, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi and Lupagen Enter into Strategic Development and Supply Agreement to Bring Cell and Gene Therapies to the Bedside
August 24, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Launches Plerixafor Injection
August 09, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Further Expands Radiology Portfolio with Launch of Gadobutrol Injection
August 08, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Introduces New Presentation for Fentanyl Citrate Injection, USP in Simplist® Ready-to-Administer Prefilled Syringes
July 11, 2023
From
Fresenius Kabi
Via
Business Wire
Expanding Access to Women’s Health Fresenius Kabi Launches Generic Fertility Treatment
July 10, 2023
From
Fresenius Kabi
Via
Business Wire
IDACIO® (adalimumab-aacf) Now Available in the United States
July 03, 2023
From
Fresenius Kabi
Via
Business Wire
Metrodora Institute, a Leader in Treating Complex Conditions, Chooses the Ivenix Infusion System from Fresenius Kabi
June 29, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Broadens Radiology Portfolio with its First-to-Market Authorized Generic, Sincalide for Injection
June 21, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio
June 14, 2023
From
Fresenius Kabi
Via
Business Wire
Supporting Patient Safety: Fresenius Kabi Expands Ready-to-Administer Portfolio with Diazepam Injection, USP in Simplist® Prefilled Syringe
May 31, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Launches RFID-Enabled Rocuronium Bromide Injection, its First Product Compatible with Bluesight's KitCheck System
May 30, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi Awarded Technology Breakthrough Agreement with Premier, Inc. for the Ivenix Infusion System
May 23, 2023
From
Fresenius Kabi
Via
Business Wire
CMS grants Fresenius Kabi permanent, product-specific Q-Code for Stimufend® (pegfilgrastim-fpgk)
May 16, 2023
From
Fresenius Kabi
Via
Business Wire
Vizient Innovative Technology Contract Awarded to Fresenius Kabi for the Ivenix Infusion System
April 17, 2023
From
Fresenius Kabi
Via
Business Wire
Stimufend® (pegfilgrastim-fpgk) Now Available in the United States
February 16, 2023
From
Fresenius Kabi
Via
Business Wire
Fresenius Kabi’s Ivenix Infusion System Goes Live at San Luis Valley Health
January 10, 2023
From
Fresenius Kabi
Via
Business Wire
< Previous
1
2
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today